Source: CureToday articles
Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.
Recent Content
- Inspirational Leader Shines Her Light Outward to Others
- Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
- Multicomponent COVID-19-Influenza Vaccine Induces Higher Immune Responses Than Standard Care Immunizations
- Advances in Radiation Improve Precision in Brain Cancer Therapy
- Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management
- Finding Strength and Joy During My Stage 4 Kidney Cancer Experience
- Expert Q&A: Expanding the Pharmacist’s Role in Community-Based Weight Management
- Children Born to Mothers With Cardiometabolic Issues Before or During Pregnancy Face Increased Risk of Childhood, Adolescent Hypertension
- IHC Testing Aims to Expand Personalized Treatment in Lung Cancer
- Patient-Centered Value is Essential Within Health Care Research